This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?


Sevilla, C., Jiménez Caballero, P.E., Alfonso, V., González-Adalid, M.


Dementia And Geriatric Cognitive Disorders, Volume: 28, No.: 3, Pages.: 196-205

Year of Publication



Background/aims: A full comparison of the satisfaction with treatment using the current Alzheimer’s disease (AD) therapies from the perspective of caregivers has not yet been done. The aim of this study was thus to find out the degree of satisfaction with the main available drug treatments in monotherapy for AD from this point of view.; Methods: A cross-sectional, multicentre study of patients with possible/probable AD according to DSM-IV/NINCDS-ADRDA criteria, on monotherapy with donepezil, galantamine, rivastigmine or memantine, was carried out. Treatment satisfaction was measured by a caregiver proxy-administration of the generic SATMED-Q questionnaire [range: 0 (not satisfied at all) to 100 (totally satisfied)], overall and in 6 domains: tolerability, efficacy, medical care, ease and convenience, impact on daily activities and overall satisfaction.; Results: A total of 829 patients were included: 63.3% women, aged 78.2 +/- 6.8 years; 546 (67.3%) on donepezil, 106 (13.1%) on rivastigmine, 99 (12.2%) on galantamine and 60 (7.4%) on memantine. SATMED-Q scores p values were adjusted by MMSE and treatment duration. Caregivers of patients on donepezil showed significantly higher SATMED-Q total (71.8 +/- 12.3; p < 0.05) and overall satisfaction domain scores (81.6 +/- 18.4; p < 0.01) than those of patients on any other drugs, as well as significantly higher ease and convenience of use domain (81.5 +/- 17.4; p < 0.01) and undesirable effects domain (96.0 +/- 12.9; p < 0.05) scores than those of rivastigmine- and galantamine-treated patients. Of the caregivers of donepezil-treated patients, 76.7% were satisfied with treatment versus 68.7, 61.4 and 46.7% of those caregivers whose patients were treated with galantamine, rivastigmine and memantine, respectively (p = 0.0002).; Conclusion: Caregivers of AD patients undergoing donepezil monotherapy seem to be more satisfied with treatment than those of patients receiving the other usual AD treatments in this study, particularly due to the ease and convenience of use of this drug. The higher level of satisfaction of these caregivers could be explained by the fact that, within the donepezil group, a high percentage of patients were treated with orally disintegrating tablets, which are easier for the patient to swallow.; Copyright 2009 S. Karger AG, Basel.

Bibtex Citation

@article{Sevilla_2009, doi = {10.1159/000236015}, url = {}, year = 2009, publisher = {S. Karger {AG}}, volume = {28}, number = {3}, pages = {196--205}, author = {C. Sevilla and P.E. Jim{&}eacute$mathsemicolon$nez Caballero and V. Alfonso and M. Gonz{&}aacute$mathsemicolon$lez-Adalid}, title = {Current Treatments of Alzheimer Disease: Are Main Caregivers Satisfied with the Drug Treatments Received by Their Patients?}, journal = {Dementia and Geriatric Cognitive Disorders} }


aged, alzheimer disease, and, caregivers, carer, cholinesterase inhibitors, donepezil, epidemiology, excitatory amino acid antagonists, female, galantamine, humans, indans, male, memantine, middle aged, neuropsychological tests, nootropic agents, on, patient compliance, patient satisfaction, phenylcarbamates, piperidines, psychiatric status rating scales, psychology, psychometrics, questionnaires, rivastigmine, satisfaction, socioeconomic factors, spain, therapeutic use, therapy

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Cohort Study

Type of Outcomes

Satisfaction with care/services

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime